DSIP (Delta Sleep-Inducing Peptide): Benefits, Dosage, and How to Get It in 2026
Medically reviewed by the Rite Aid Health Team · Last updated July 9, 2026
DSIP — Delta Sleep-Inducing Peptide — is a naturally occurring neuropeptide studied for its role in sleep regulation and stress resilience. Its compounding name is Emideltide. It takes its name from research showing it promotes slow-wave, or delta, sleep.
It is one of the 12 peptides the FDA removed from its Section 503A Category 2 list in April 2026, and one of seven peptides under formal advisory review on July 23–24, 2026 — where it appears as Emideltide. In the broader peptide therapy category, DSIP belongs with sleep, stress, and recovery rather than weight loss or growth-hormone protocols.
Almost done
We sent the first email to .
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then your discount is reserved
Once you confirm, we reserve your discount and will notify you when peptide services launch.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
What is DSIP?
DSIP is a small, naturally occurring neuropeptide first identified in research on sleep. The name describes the effect observed in early studies: it promotes delta-wave (slow-wave) sleep, the deepest stage of non-REM sleep.
In a compounding-pharmacy context it is referred to as Emideltide. DSIP occurs naturally in the body, and it is not FDA-approved as a drug in the United States.
Benefits and uses
What the research has examined — with the honest caveat that human clinical data is limited:
- Sleep regulation. The most-studied effect; DSIP promotes slow-wave sleep in research settings and has been investigated for sleep disturbances.
- Stress resilience. Studied for effects on the stress response and adaptation.
- Pain modulation. Some research has looked at a possible role in pain perception.
- Hormone regulation. Investigated for possible effects on hormone release, though this is not well established.
State the limit plainly: DSIP has a research history spanning decades, but rigorous, large-scale human clinical trials are limited, and several of its proposed effects are not firmly established.
How it works
DSIP's mechanism is not fully understood. In research it promotes slow-wave (delta) sleep and appears to interact with systems that regulate the stress response and circadian rhythm, but the exact receptors and pathways it acts through have not been definitively mapped.
This is an honest gap rather than a settled mechanism — the peptide is named for an observed effect, not a fully characterized pathway.
Dosage and administration
DSIP is administered by subcutaneous injection. There is no FDA-approved DSIP product and no official dosing guideline. Protocols vary, and DSIP is typically used in the evening given its sleep-related effects. Dosing should be set by a prescribing provider.
For a peptide your clinician prescribed and an appropriate pharmacy prepared, use the peptide dosage calculator to convert a prescribed target dose into the right volume for your vial size.
Side effects and safety
DSIP is generally reported to be well tolerated in research, with few reported adverse effects. Because it occurs naturally and has been studied for decades, acute tolerability appears favorable, but long-term human safety data is limited. Anyone using DSIP should work with a provider and establish a safety baseline.
How to get DSIP in 2026
The regulatory status changed this year:
- For several years DSIP sat on the FDA's Section 503A Category 2 list, which effectively blocked compounding pharmacies from preparing it.
- On April 15, 2026 the FDA removed DSIP (as Emideltide, and 11 other peptides) from that Category 2 list.
- A Pharmacy Compounding Advisory Committee meeting on July 23–24, 2026 will evaluate whether Emideltide (DSIP) should be formally added to the authorized bulk-substances list compounding pharmacies can use.
Until that process completes, do not treat the advisory review as approval. Products sold online "for research use only" are not approved, manufactured, or quality-controlled for human use, and buying them carries both quality and legal risk.
Almost done
We sent the first email to .
Confirm your email to secure 20% off your first compounded-peptide order. We'll notify you when consultations and ordering open.
-
1
Confirm your email
Open the first email and click the confirmation link.
-
2
Only after step 1
Then your discount is reserved
Once you confirm, we reserve your discount and will notify you when peptide services launch.
The first email should arrive within a minute. Do not see it? Check spam or promotions.
Get 20% off your first compounded-peptide order
Join the early-access waitlist and we'll notify you the moment consultations and ordering open.
DSIP vs other sleep and longevity peptides
DSIP is often considered alongside other peptides used for recovery and longevity protocols. It is compared with Epitalon, studied for melatonin and circadian regulation, and grouped with Semax in the broader research-peptide set.
For a longer-term protocol, compare DSIP with other anti-aging and longevity peptides.
Blood work to track DSIP
DSIP doesn't have a single direct biomarker, so tracking focuses on safety:
- Comprehensive metabolic profile — liver enzymes and kidney function, the safety baseline for any peptide cycle.
Test before you start and again at 4–6 weeks.
Baseline tests before a peptide cycle
Check safety and response markers before starting. These tests help establish a baseline for liver, kidney, glucose, hormone, and recovery tracking.
References
For general education only — not medical advice or a treatment recommendation. Peptides are not a substitute for care from a licensed provider. Talk to a qualified healthcare professional before you start, stop, or change any peptide, medication, or supplement.
FAQ
Most commonly studied for sleep regulation — it promotes slow-wave (delta) sleep in research — and for stress resilience. Human clinical data is limited, and several proposed effects are not firmly established.
DSIP/Emideltide is under FDA advisory review in July 2026, and FDA staff documents recommend caution because human safety and effectiveness data are limited. "Research use only" products are not approved for human use.
Emideltide is the compounding-pharmacy name for DSIP (Delta Sleep-Inducing Peptide). It is the same peptide, referred to under the name used in the FDA compounding process.
DSIP is given by subcutaneous injection, typically in the evening given its sleep-related effects. There is no FDA-approved product or official dosing. Dosing should be set by a prescribing provider.
Its mechanism is not fully understood. In research it promotes delta (slow-wave) sleep and appears to interact with stress-response and circadian systems, but the exact receptors and pathways have not been definitively mapped.
DSIP is generally reported to be well tolerated in research, with few reported adverse effects. Long-term human safety data is limited.